Medical Use
Blincyto, which contains blinatumomab, is a bispecific CD19-directed CD3 T-cell engager. It is used for:
- -Treating B-cell precursor acute lymphoblastic leukemia (ALL) in patients who are in their first or second complete remission with minimal residual disease (MRD) of 0.1% or greater.
- -Managing relapsed or refractory B-cell precursor ALL.
Warning & Precautions
Evaluate patients receiving blinatumomab injections for any signs or symptoms of neurological toxicities. Advise outpatients on Blincyto to contact their healthcare provider if they experience any neurological symptoms.
Monitor patients on Blincyto for signs of infection and provide appropriate treatment as needed.
Regularly assess laboratory parameters, including WBC count and absolute neutrophil count, during blinatumomab infusion. Interrupt the medication if prolonged neutropenia is observed.
Check levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), and total blood bilirubin before starting and during Blincyto 35 mcg treatment.
Evaluate patients who show signs of pancreatitis. Management may require temporary interruption or discontinuation of Blincyto and dexamethasone.
Healthcare professionals advise against receiving live virus vaccines for at least two weeks before starting Blincyto 35 mcg treatment, during treatment, and until the immune system recovers after the last cycle of Blincyto.
Documentation Availability
Documents required to import Blincyto to India?
Blincyto (Blinatumomab) injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing Blincyto (Blinatumomab) injection around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Blincyto®?
The generic name for Blincyto® is blinatumomab.
Is Blincyto® approved by the FDA?
Yes, Blincyto® was approved by the FDA in 2014.
What type of drug is Blincyto®?
Blincyto® is a prescription medication used to treat patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) of 0.1% or greater, as well as those with relapsed or refractory B-cell precursor ALL.
What dosage and form is Blincyto® available in?
Blincyto® is available as a 35 mcg lyophilized powder in a single-use vial for reconstitution.
What are the ingredients in Blincyto®?
The active ingredient in Blincyto® is blinatumomab. The inactive ingredients include citric acid monohydrate, lysine hydrochloride, polysorbate 80, trehalose dihydrate, and sodium hydroxide in preservative-free sterile water for injection.
Is Blincyto® considered chemotherapy?
Blincyto® is an immunotherapy medication that works with the immune system to target and destroy cancer cells. Blinatumomab, the active ingredient, is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 on B-lineage cells and CD3 on T cells.
What is the latest FDA approval for Blincyto®?
On June 14, 2024, the FDA approved Blincyto® for use in adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during the consolidation phase of chemotherapy. This approval applies regardless of measurable residual disease (MRD) status, broadening its use to more patients.
How effective is Blincyto® in the consolidation phase of B-ALL treatment?
Clinical trials have demonstrated that adding Blincyto® to a multiphase consolidation chemotherapy regimen significantly improves overall survival rates compared to chemotherapy alone. In the E1910 study, the three-year overall survival rate was 84.8% for patients receiving Blincyto® plus chemotherapy, compared to 69% for those on chemotherapy alone. The five-year overall survival also showed substantial improvement, highlighting Blincyto®'s potential to enhance long-term outcomes.
What makes Blincyto® a unique treatment option for B-ALL?
Blincyto® is the first and only bispecific T-cell engager (BiTE) therapy approved for the consolidation treatment of B-ALL, regardless of MRD status. This innovative immunotherapy leverages the body’s immune system to target and eliminate cancer cells by bringing T-cells into close proximity with cancerous B-cells.
What are the new findings from recent clinical trials regarding Blincyto®?
Recent clinical trials, including the E1910 and 20120215 studies, have confirmed Blincyto®'s effectiveness in improving overall survival and relapse-free survival rates in both adult and pediatric patients with B-ALL. These trials emphasize Blincyto®'s significant impact on long-term patient outcomes, particularly in the consolidation phase of chemotherapy.
How does Blincyto® fit into the current treatment landscape for B-ALL?
Blincyto®'s approval for use in the consolidation phase marks a significant shift in the standard of care for B-ALL. By incorporating this immunotherapy into earlier treatment phases, patients may achieve deeper remissions and improved survival outcomes, potentially reducing the risk of relapse.
How to order Blincyto® online in India?
Blincyto® can be ordered online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
